ZG2273

ZG2273 is an early-stage preclinical drug candidate being developed by Suzhou Zelgen Biopharmaceuticals (Zelgen). The program is part of Zelgen's portfolio of therapies discovered using its AI-driven drug discovery platform and structure-activity relationship (SAR) screening methodologies, which are designed to identify small-molecule drugs for traditionally 'undruggable' biological targets. While Zelgen's broader pipeline includes advanced biologics such as T-cell engagers and bispecific or multispecific antibodies, ZG2273 is specifically associated with the company's small-molecule discovery efforts. As of current public disclosures, the specific biological target, mechanism of action, and intended therapeutic indications for ZG2273 remain proprietary and have not been released.